Allosteric activation of ADAMTS13 by von Willebrand factor by Muia, Joshua et al.
Allosteric activation of ADAMTS13 by von
Willebrand factor
Joshua Muiaa,1, Jian Zhua,1, Garima Guptaa, Sandra L. Haberichterb, Kenneth D. Friedmanb, Hendrik B. Feysc,
Louis Deforched, Karen Vanhoorelbeked, Lisa A. Westfielda, Robyn Rothe, Niraj Harish Toliaf,g, John E. Heusere,
and J. Evan Sadlera,f,2
Departments of aMedicine, eCell Biology and Physiology, fBiochemistry and Molecular Biophysics, and gMolecular Microbiology and Microbial Pathogenesis,
Washington University School of Medicine, St. Louis, MO 63110; bBlood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI 53201; cTransfusion
Research Center, Belgian Red Cross-Flanders, Ghent, Belgium; and dLaboratory for Thrombosis Research, KU Leuven Kulak, 8500 Kortrijk, Belgium
Edited* by David Ginsburg, University of Michigan Medical School, Ann Arbor, MI, and approved September 26, 2014 (received for review July 13, 2014)
The metalloprotease ADAMTS13 cleaves von Willebrand factor
(VWF) within endovascular platelet aggregates, and ADAMTS13
deficiency causes fatal microvascular thrombosis. The proximal
metalloprotease (M), disintegrin-like (D), thrombospondin-1 (T),
Cys-rich (C), and spacer (S) domains of ADAMTS13 recognize a
cryptic site in VWF that is exposed by tensile force. Another seven
T and two complement C1r/C1s, sea urchin epidermal growth
factor, and bone morphogenetic protein (CUB) domains of un-
certain function are C-terminal to the MDTCS domains. We find
that the distal T8-CUB2 domains markedly inhibit substrate
cleavage, and binding of VWF or monoclonal antibodies to distal
ADAMTS13 domains relieves this autoinhibition. Small angle X-ray
scattering data indicate that distal T-CUB domains interact with
proximal MDTCS domains. Thus, ADAMTS13 is regulated by sub-
strate-induced allosteric activation, which may optimize VWF
cleavage under fluid shear stress in vivo. Distal domains of other
ADAMTS proteases may have similar allosteric properties.
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After vascular injury, platelets adhere to von Willebrandfactor (VWF) multimers bound to endothelial cell surfaces
and connective tissue. The force of flowing blood on a growing
platelet-rich thrombus stretches the central A2 domain of VWF
and exposes a Tyr1605-Met1606 cleavage site for ADAMTS13 (Fig.
1A) (1–5), a metalloprotease that severs VWF and releases ad-
herent platelets. Deficiency of ADAMTS13 disrupts this feedback
regulatory mechanism and causes thrombotic thrombocytopenic
purpura (TTP), which is characterized by life-threatening micro-
vascular thrombosis (3, 6, 7).
The recognition and cleavage of VWF is a formidable challenge.
VWF and ADAMTS13 occur at ∼10 μg/mL and ∼1 μg/mL, re-
spectively, compared with total plasma protein of ∼80,000 μg/mL.
ADAMTS13 is constitutively active and has no known inhibitors in
vivo. Nevertheless, VWF is the only identified ADAMTS13 sub-
strate, and VWF is resistant to cleavage until subjected to fluid
shear stress (8), adsorbed on a surface (9), or treated with dena-
turants (8, 10). This specificity depends on structural features of
both ADAMTS13 and VWF that have not been characterized fully.
The proximal metalloprotease (M), disintegrin-like (D), throm-
bospondin-1 (T), Cys-rich (C), and spacer (S) domains domains of
ADAMTS13 bind to cryptic sites that are uncovered by unfolding
VWF domain A2 (11-15) (Fig. 1B), and these interactions are re-
quired for efficient cleavage of VWF or peptide substrates. More
distal ADAMTS13 domains bind to sites in or near VWF do-
main D4 that are always available (16–18). Deletion of distal
ADAMTS13 domains impairs the cleavage of VWF multimers
in vitro (16, 19) and increases VWF-dependent microvascular
thrombosis in vivo (20) but accelerates the cleavage of peptide
substrates (12, 13). In addition, ADAMTS13 cleaves guanidine
hydrochloride-treated VWF multimers with an apparent Km of
∼15 nM (21), which is 100-fold lower than the Km of ∼1.6–
1.7 μM for peptide substrates that are based on the sequence of
VWF domain A2 (12, 14). These striking differences suggest that
distal T or complement c1r/c1s, sea urchin epidermal growth
factor, and bone morphogenetic protein (CUB) domains regu-
late ADAMTS13 activity. We have now shown that these distal
domains inhibit ADAMTS13, and binding to VWF relieves
this autoinhibition.
Results
Activation of ADAMTS13 by Antibodies and Low pH. Evidence for
allosteric regulation was obtained unexpectedly in the course of
analyzing plasma samples from patients with TTP. The majority
of adult patients with acquired TTP have autoantibodies that
inhibit ADAMTS13 and reduce its activity in plasma to <5% of
normal, but one patient proved to be a remarkable exception.
When assayed with a fluorogenic ADAMTS13 substrate, VWF71
(Fig. 1B) (22), patient BCW49 had high-titer autoantibodies that
paradoxically activated exogenous ADAMTS13 ∼threefold (Fig.
1C). Activation occurred at pH 7.4, which is characteristic of
blood, but not at pH 6, which is used routinely for clinical
ADAMTS13 assays (23). Furthermore, BCW49 plasma had no
effect on the activity of MDTCS at either pH 7.4 or pH 6.
The loss of pH dependence for MDTCS suggested a regulatory
function for the distal domains that are missing from this trun-
cated ADAMTS13 construct. We (22) and others (23, 24) have
observed that full-length ADAMTS13 is most active at pH 6, with
markedly decreased activity at pH 7.4 (Fig. 1D and Fig. S1). This
phenomenon has been attributed to ionization of a Zn2+-bound
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water molecule in the active site (24). However, MDTCS had
approximately the same activity at both pH values, which excludes
titration of the active site or the substrate. Instead, distal domains
mediate the autoinhibition of ADAMTS13 at physiological pH.
The protonation of specific residues at pH 6 alters critical
interactions between distal and proximal ADAMTS13 domains
and relieves this autoinhibition (Fig. 1D). The autoantibodies of
patient BCW49 also can induce an activated conformation of
ADAMTS13 even at physiological pH (Fig. 1C).
Allosteric Activation of ADAMTS13 by VWF. We screened anti-
ADAMTS13 monoclonal antibodies for properties similar to
those of BCW49 plasma and identified several that increased the
rate of VWF71 cleavage (Fig. 2A). When combined at saturating
concentrations (Fig. S2), certain antibodies that recognized T67,
T8, and CUB domains had additive effects and activated
ADAMTS13 up to ∼4.2-fold at pH 7.4 (Fig. 2A), which is com-
parable to the magnitude of ADAMTS13 activation achieved by
changing to pH 6 (Fig. 1D). These antibodies had markedly de-
creased effects on ADAMTS13 activity at pH 6 (Fig. S2). Auto-
antibodies in BCW49 plasma also bound to the CUB domains (Fig.
2B). These data suggest that specific distal T and/or CUB domains
contribute to autoinhibition of ADAMTS13 at physiological pH.
Only some monoclonal antibodies that recognize a particular
distal domain can activate ADAMTS13 (Fig. 2A), and these dif-
ferences correlate with epitope specificity. For example, anti-T67
antibody 7C4 activates ADAMTS13 but 8C10 does not, and these
antibodies bind distinct sites on ADAMTS13. Activating anti-T8
antibodies 14D2 and 19H4 bind competitively to ADAMTS13 at
a site distinct from that recognized by nonactivating anti-T8 anti-
bodies 11E2 and 20A5. Finally, anti-CUB antibodies 12D4 and
12H6 recognize different epitopes, but 12D4 activates ADAMTS13,
whereas 12H6 does not (Fig. 2A). These results suggest that acti-
vating antibodies bind and stabilize an activated ADAMTS con-
formation, whereas nonactivating antibodies show no preference for
such a conformation.
Several proximal ADAMTS13 domains participate in recog-
nition of the extended VWF A2 domain that contains the scissile
Tyr1605-Met1606 bond (12–15) (Fig. 1B). We prepared a series of
fluorogenic substrates to determine whether activation involved
specific proximal ADAMTS13 domains that engage distinct
segments of VWF (Fig. 1B). As expected (13), the cleavage rate
decreased as the substrate length decreased. However, the mag-
nitude of activation by low pH (Fig. 2C) increased to ∼ninefold
even for the shortest substrate VWF25, even though VWF25
interacts only with the MD domains of ADAMTS13 (13). The
activation ratios, which correspond to the change in free energy of
transition state stabilization (ΔΔGT) (25), do not depend strongly
on substrate length. In addition, antibodies that increased the
cleavage of fluorogenic substrates by ADAMTS13 had no effect
on MDTCS (Fig. 2C).
More importantly, adding VWF or recombinant VWF D4
markedly increased fluorogenic substrate cleavage (Fig. 2D).
Staphylococcal V8 protease cleaves VWF after Glu2129 between
the VWD4 and C8-4 subdomains of D4 and more slowly after
Glu1673 between the A2 and A3 domains (26) (Fig. S3). These
proteolytic fragments—SPI, SPII, and SPIII—had little effect on
ADAMTS13 (Fig. 2D), suggesting that a functional ADAMTS13
binding site requires cooperation between motifs on both sides of
the V8 cleavage site in the D4 domain.
These results indicate that the VWF D4 domain binds distal
ADAMTS13 domains and allosterically activates the N-terminal
M domain. The interaction of these distal domains with proximal
MDTCS domains might be expected to reduce the affinity of
ADAMTS13 binding to VWF A2 domain sequences that contain
the scissile Tyr-Met bond, and this prediction was confirmed by
using ADAMTS13(E225Q) variants that can bind substrates
normally but cannot cleave them (17) (Fig. S4). MDTCS bound
to a chimeric GST-VWF73 construct with a Kd of 210 ± 30 nM
(SE), whereas ADAMTS13 bound slightly less tightly with a Kd
of 440 ± 50 nM (SE).
The mutation G1505E, which was identified in patients with von
Willebrand disease type 2A, prevents complete folding of VWF
domain A2, exposes the scissile bond, and allows ADAMTS13 to
cleave it rapidly and completely in the absence of shear stress (27).
MDTCS bound to VWF construct A1-CK(G1505E) but did not
bind to wild-type A1-CK (with a folded A2 domain) or to con-
struct D4-CK (with no A2 domain). In contrast, ADAMTS13 did
bind to VWF constructs D4-CK and A1-CK, presumably at the
D4 site. ADAMTS13 also bound to A1-CK(G1505E) with in-
creased affinity, which is consistent with binding to both A2 and
D4 sites (Fig. S4).
ADAMTS13 Distal Domains Facilitate VWF Cleavage Under Shear
Stress. The natural substrate of ADAMTS13, multimeric plasma
VWF, is resistant to cleavage until subjected to fluid shear stress
that exposes the cleavage site in the A2 domain. The time course
of this reaction can be analyzed by vortexing plasma VWF with
ADAMTS13 variants and detecting specific cleavage products by
Western blotting (16, 17). Under these conditions, full-length
ADAMTS13 cleaved VWF ∼1.7-fold faster than MDTCS (Fig. 3
A and C), even though ADAMTS13 is ∼fourfold less active to-
ward small peptide substrates (Fig. 1). The preferential cleavage
of VWF by ADAMTS13 is not explained by an effect of shear
stress on the enzyme, because vortexing ADAMTS13 with VWF71
for 10 min increased product generation only 1.15 ± 0.07-fold
Fig. 1. Activation of ADAMTS13 by autoantibodies from a patient with TTP
or by low pH. (A) Structure of ADAMTS13. (B) Fluorogenic substrates ter-
minate at VWF residues indicated by arrows. Each substrate has Lys1617
replaced with Arg, N-terminal Gly modified with IRDye QC-1 (QC1), and
Asn1610 replaced by Cys and modified with DyLight 633 (DyL) (22). The ar-
rowhead indicates the cleaved Tyr-Met bond. Secondary structure elements
of the VWF A2 domain (11) are indicated below and segments that interact
with specific ADAMTS13 domains (13) are indicated above the sequence. (C)
BCW49 plasma activated ADAMTS13 with a titer of 9.6 U at pH 7.4 (orange
squares), but not at pH 6.0 (orange circle). BCW49 plasma did not activate
MDTCS at pH 6 (blue circle) or pH 7.4 (blue circle). (D) Rates of VWF71
cleavage were determined as a function of pH for ADAMTS13 (orange cir-
cles) and MDTCS (blue circles). Error bars indicate 95% confidence intervals
and if not shown are smaller than the symbols.
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(SD); this small effect of vortexing may be due to frictional heating
of the reaction.
Anti-CUB antibody 12D4 increased the rate of VWF cleav-
age ∼twofold (Fig. 3 B and C). Thus, distal ADAMTS13 domains
that bind VWF domain D4 confer an advantage for cleaving VWF
that can be increased further by allosteric activation. Although anti-
T8 antibody 19H4 also accelerates the cleavage of peptide sub-
strates (Fig. 2A), it had no effect on the cleavage of VWF (Fig. 3D).
ADAMTS13 Distal Domains Are Adjacent to Its Proximal Domains. The
regulation of ADAMTS13 metalloprotease activity by its distal
T-CUB domains implies that proximal and distal domains are
close enough to make contact, and small angle X-ray scattering
(SAXS) data (Fig. 4A) indicate that ADAMTS13 does have such
a structure. Pair distance distributions (Fig. 4B) show that
MDTCS, MT8, and ADAMTS13 have maximum dimensions of
∼140 Å, ∼200 Å, and ∼230 Å, respectively. For comparison,
a molecular model of ADAMTS13 has a maximum extended
length of ∼500 Å (Fig. 4C). Agreement was excellent between an
atomic model for MDTCS and experimental scattering profiles
(χ = 1.86) (28) (Fig. 4A) or ab initio envelopes (Fig. 4D). The
envelopes for full-length ADAMTS13 (Fig. 4E) are too compact
for fully extended ADAMTS13 but readily accommodate a folded
or condensed conformation. Specific flexible segments have not
been identified, but the extended linkers after T4 and T8 are
susceptible to proteolysis by thrombin, plasmin, or elastase (29,
30) and may act as hinges. Comparisons of SAXS envelopes for
ADAMTS13 and construct MT8, which lacks both CUB
domains, indicate that the CUB domains are adjacent to proxi-
mal ADAMTS13 domains and occupy a bulge in the envelope
for ADAMTS13 (Fig. 4E) that is missing from the envelope for
MT8, which cannot accommodate the CUB domains in this lo-
cation (Fig. 4F). This folded conformation would enable distal
T7-CUB domains to allosterically regulate ADAMTS13 by var-
iably occluding the active site and substrate binding exosites. The
occurrence of condensed ADAMTS13 is supported by quick-
freeze deep-etch EM, which shows both elongated and folded
conformations for ADAMTS13 (Fig. 4G).
Discussion
Our results indicate that VWF promotes its own destruction by
allosterically activating ADAMTS13, and this mechanism could
have evolved to balance the competing needs to promote VWF-
dependent hemostasis and prevent VWF-dependent thrombosis.
In addition, the finding that VWF activates ADAMTS13 raises
Fig. 2. Allosteric activation of ADAMTS13. (A) Monoclonal anti-ADAMTS13 antibodies were added to ADAMTS13 assays with pooled normal plasma (PNP).
Reaction rates were normalized to the rate with PNP only. The location of epitopes is indicated. Activation values >1.5× control (orange bars) are significantly
different from the PNP reference condition (P < 0.05). (B) Recombinant ADAMTS13 and MT8 were immunoprecipitated with antibodies in PNP or BCW49
plasma, and the recovered enzyme was assayed with substrate VWF71. (C and D) MDTCS (blue bars) and ADAMTS13 (orange bars) were assayed with the
indicated fluorogenic substrates (Fig. 1B). (C) Bars indicate the ratio of reaction rates at pH 6 and pH 7.4 (Left), or the ratio of reaction rates with and without
activating monoclonal antibodies 7C4, 19H4, and 12D4 (Right). (D) Plasma VWF multimers (0.45 μM) or VWF D4 monomers (40 μM) increased the activity of
ADAMTS13 toward VWF71. SPI (2 μM), SPII (2 μM), and SPIII (0.54 μM) fragments of VWF, which are cleaved within the D4 domain by V8 protease, had little or
no effect on ADAMTS13 activity. Error bars indicate 95% confidence intervals.
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the possibility that other ADAMTS13 cofactors occur on cell
surfaces, in blood, or in extracellular matrix.
For human ADAMTS13, binding to VWF D4 allosterically
activates ADAMTS13, increasing its catalytic activity, but binding to
VWF D4 also positions ADAMTS13 on the substrate where it can
act rapidly when shear stress exposes the scissile bond in the adja-
cent A2 domain. These twomechanisms work together to focus pro-
teolytic activity on VWF multimers. However, mouse ADAMTS13
may rely mainly on substrate binding rather than allostery.
Some mouse strains express a “long” Adamts13 that is similar to
full-length human ADAMTS13. Other strains have an intracisternal
A-particle (IAP) retrotransposon inserted in the Adamts13 gene
and express a “short” Adamts13 that is truncated after the T6 (31).
Long Adamts13 cleaves VWF multimers ninefold faster than short
Adamts13, which is consistent with the role we propose for binding
of distal domains to VWF D4 (19). However, long and short
Adamts13 reportedly have similar activity toward small substrates
that are similar to VWF71 (19, 31). Therefore, in contrast to human
ADAMTS13, deletion of the distal T7-CUB2 domains may not
activate mouse Adamts13, which suggests that allosteric activation
is less significant than for human ADAMTS13 or depends on
domains other than T7-CUB2. Further study is required to de-
termine the relative importance of substrate binding and allosteric
activation for ADAMTS13 in humans, mice, and other vertebrates.
The allosteric properties of ADAMTS13 are likely to have
clinical relevance. Relatively modest decreases in ADAMTS13
activity seem to increase the risk of ischemic stroke and myo-
cardial infarction (32–34). In animal models, ADAMTS13 de-
ficiency promotes vascular inflammation and atherosclerosis (35).
Therefore, inherited or acquired defects in the allosteric regulation
of ADAMTS13 could inhibit VWF cleavage and contribute to
thrombosis in these conditions.
Conversely, agents that block allosteric activation could be
useful to treat bleeding caused by excessive proteolysis of VWF,
which occurs mainly in two settings. Von Willebrand disease type
2A frequently is due to mutations like G1505E (27) that impair
the folding of the VWF A2 domain and allow cleavage by
ADAMTS13 even in the absence of fluid shear stress. As a result,
the VWF multimers that circulate in the blood are too small for
effective hemostasis (36, 37). Acquired von Willebrand syndrome
also is characterized by deficiency of the largest VWF multimers,
often as a result of pathologically increased fluid shear stress that
promotes cleavage by ADAMTS13. For example, this type of
acquired von Willebrand syndrome is very common in patients
with implanted left ventricular assist devices, who experience re-
current major gastrointestinal bleeding as a result (38). Because
ADAMTS13 can be allosteric activated by ∼fourfold to ∼10-fold, an
inhibitor of allosteric activation could reduce ADAMTS13 activity to
no lower than ∼10%, which is not low enough to cause TTP (6, 7)
but may be useful to treat bleeding. The feasibility of this ap-
proach is supported by a study demonstrating that a monoclo-
nal antibody against the VWF D4 domain inhibits ADAMTS13
Fig. 3. Cleavage of VWF by ADAMTS13 under fluid shear stress. VWF cleavage
products were detected by SDS/PAGE and immunoblotting with anti-VWF. The
arrowheads indicate the 350-kDa VWF fragment produced by ADAMTS13.
Plasma VWF (40 nM) was sheared for the indicated times (seconds) with (A)
MDTCS or ADAMTS13 (50 nM), or (B) with ADAMTS13 (50 nM) without or with
monoclonal antibody 12D4 (40 μg/mL). (C) Densitometric analysis to compare the
rate of VWF cleavage by ADAMTS13 without (orange squares) or with (green
triangles) monoclonal antibody 12D4, or by MDTCS (blue circles). Values are
normalized to cleavage at 300 s by ADAMTS13 alone and plotted as the mean ±
SE for twoexperiments. (D) Duplicate reactionswithADAMTS13were sheared for
300 swithout orwithmonoclonal antibody 19H4 (100 μg/mL) or 12D4 (40 μg/mL).
Control reactions were sheared for 300 s in the presence of 10 mM EDTA.
Fig. 4. ADAMTS13 structure by EM and SAXS. Scattering profiles (A) and pair
distribution functions (B) for MDTCS, (red) MT8 (orange), and ADAMTS13
(blue). (C) Molecular model of ADAMTS13. (D–F) Ab initio envelopes calcu-
lated from scattering profiles for (D) MDTCS (red mesh), (E) ADAMTS13 (blue
mesh), or (F ) MT8 (orange mesh) superimposed on an atomic model of
MDTCS (D, cartoon; E and F, surface), MT8, or ADAMTS13 (E and F, sur-
face). The arrow indicates a difference between MT8 and ADAMTS13
maps that corresponds to the proposed location of CUB domains. (G)
Quick-freeze deep-etch EM of ADAMTS13.
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binding and markedly reduces the excessive degradation of VWF
multimers in an ex vivo model using a HeartMate II left ventric-
ular assist device (39).
Like ADAMTS13, other ADAMTS proteases and related
ADAMTSL proteins also have complex C-terminal structures
with up to 15 T repeats and variable numbers of proteoglycan,
a protease and lacunin (PLAC) domain, and Gon-1 modules
that are likely to mediate regulatory protein–protein interactions
(40, 41). For example, N-terminal procollagen processing depends
on ADAMTS2, and defects in ADAMTS2 cause a variant of
Ehlers-Danlos syndrome (41). Microfibrils regulate the activa-
tion of TGF-β, which is force-dependent (42), as is the processing
of VWF by ADAMTS13 (8, 11). The biogenesis of microfibrils
involves several ADAMTS and ADAMTSL proteins, and muta-
tions in them cause developmental disorders such as Weill-
Marchesani syndrome (ADAMTS10, ADAMTS17), geleophysic
dysplasia (ADAMTSL2), and ectopia lentis (ADAMTS17,
ADAMTSL4) (41, 43). The distal domains of these homologous
proteins share many structural features with ADAMTS13 and
may have similar allosteric properties that are essential for their
biological functions.
Materials and Methods
Antibodies.Mouse monoclonal antibodies to ADAMTS13 were made by DNA
immunization with a plasmid encoding human ADAMTS13, i.p. injection of
recombinant human ADAMTS13, and isolation of hybridomas by standard
methods (44). Epitopes were localized and binding affinities determined by
ELISAs (44) and immunoprecipitation (45) using a panel of ADAMTS13
constructs with C-terminal truncations or internal domain deletions.
Plasma samples from patients with TTP or healthy donors were obtained
with informed consent under protocols approved by the institutional review
board of Washington University or BloodCenter of Wisconsin.
ADAMTS13 Assays. Fluorogenic peptide substrate FRETS-rVWF71 (VWF71)
has an N-terminal Gly followed by VWF Gln1599-Arg1668 with mutations
N1610C and K1617R. The N terminus is modified with IRDye QC-1 N-
hydroxysuccinimide ester (Li-COR), and Cys1610 is modified with DyLight
633 maleimide (Thermo Scientific) (22). FRETS-rVWF25, FRETS-rVWF44,
and FRETS-rVWF62 were prepared similarly except with C-terminal resi-
dues Asp1622, Arg1641, and Arg1659, respectively.
ADAMTS13 was assayed with fluorogenic substrates as previously de-
scribed (22). Standard assays included 50 mM Bis-Tris (pH 6) or Hepes
(pH 7.4), 150 mM NaCl, 10 mM CaCl2, 0.05% Tween-20, 1 mg/mL BSA, 1 μM
fluorogenic substrate, and PNP or recombinant ADAMTS13 variants in a total
volume of 200 μL. Reaction was initiated by adding buffer containing sub-
strate to enzyme in 96-well white microplates (Optiplate-96, PerkinElmer) at
30 °C. Product generation was monitored as an increase in fluorescence using
a Victor2V Multilabel Counter (PerkinElmer) or Synergy H1 Hybrid Multi-Mode
Microplate Reader (Biotek) with 635 ± 10-nm excitation and 660 ± 10-nm
emission filters. Assays by this method have an interassay coefficient of vari-
ation of <2% (22).
ADAMTS13 activity as a function of pH was assayed similarly, except the
buffer included 20 mM Bis-Tris, 20 mM Hepes, and 20 mM Tris·HCl at pH
values between pH 6 and pH 7.4 in increments of 0.2 pH unit.
Shear-induced cleavage of VWF was assayed as described previously (16,
17), with modifications. Reactions (30 μL total volume) were performed in
50 mM Hepes (pH 7.4), 150 mM NaCl, 5 mM CaCl2, and 1 mg/mL BSA at room
temperature with plasma VWF (40 nM) and ADAMTS13 variants (50 nM)
without or with 10 mM EDTA, without or with fluid shear stress, and with or
without antibody 12D4 or 19H4. To be sure that ADAMTS13 was saturated
with antibodies, the final concentrations of 19H4 (100 μg/mL) and 12D4
(40 μg/mL) were ∼20-fold higher than the EC50 for activating ADAMTS13
toward VWF71 (Fig. S2). Reactions were stopped by adding EDTA to 10 mM.
Samples (1–5 μL) were mixed with 2× Tris-glycine SDS sample buffer,
degassed, heated 10 min at 70 °C, and analyzed by electrophoresis on Novex
4% Tris-glycine SDS gels. Gels were immersed in PBS containing 1 mM
β-mercaptoethanol for 10 min with gentle shaking, washed twice with PBS,
and rinsed with water. Proteins were transferred to a PVDF membrane for
10 min at 23 V using an iBlot device (Thermo Scientific Life Technologies).
The membrane was washed in PBS for 5 min, blocked in casein blocking
buffer for 1 h, and incubated overnight in blocking buffer containing
1:2,500 HRP-labeled rabbit anti-human VWF antibody (P226, Dako). Labeled
proteins were detected by chemiluminescence (WesternBright ECL HRP,
Advansta) and analyzed with Image Studio 4.0 (LI-COR).
ADAMTS13 and VWF Proteins. SI Materials and Methods includes detailed
procedures for the further purification of human plasma VWF (Laboratoire
Français du Fractionnement et des Biotechnologies, Lille, France), prepara-
tion of staphylococcal V8 protease fragments SPI, SPII, and SPIII, and the
production of recombinant ADAMTS13 and VWF variants for enzymatic
characterization and antibody epitope localization. The concentration of
proteins was determined in BCA protein assays (Thermo Scientific Pierce)
standardized with BSA.
Activation Assays. Pooled normal Li+-heparin plasma (PNP) was prepared
from ≥35 healthy donors. Plasma samples from patients with TTP were
screened for activation of ADAMTS13 in assays (200 μL) with FRETS-rVWF71,
50 μL PNP, and 50 μL of plasma. Monoclonal antibodies were screened with
25 μL PNP and ∼2 μg of antibody per reaction. VWF and VWF fragments were
added at varying concentrations. EC50 values for activators were determined
from assays of serial dilutions and nonlinear regression (22). Differences
between mean values were assessed with the unpaired Student t test.
Binding Assays. Dissociation constants (Kd) were determined by biolayer in-
terferometry (BLI) using an Octet RED96 (ForteBio). GST-VWF73 (12) was
captured by biotinylated anti-GST antibody bound to streptavidin-biosensors.
D4-CK, A1-CK, and A1-CK(G1505E) were captured on Ni-NTA biosensors.
Binding to ADAMTS13 proteins was performed in 20 mM Hepes (pH 7.4),
150 mM NaCl, 2 mg/mL BSA, and 0.02% Tween 20. A buffer-only reference
was subtracted from all curves. Affinities were determined from global ki-
netic analysis for a 1:1 binding model using Octet RED software, version 5.2.
Molecular Modeling. An atomic model of MDTCS was constructed from the
crystallographic structure of DTCS domains (15) and a homology model of
MD domains (13) that was based on ADAMTS4 (46).
Full-length ADAMTS13was built using HHpred (47) to model distal T domains,
CUB domains, and linkers after T4 and T8. Templates for T domains included
1w0r, 3t5o, 3ghm, 3r6b, 1lsl, and 1vex. Templates for CUB domains included
2qqk, 3kq4, 1spp, 2qqm, and 2wno.
Electron Microscopy. Deep-etch replicas were prepared by adsorbing
ADAMTS13 on acid-cleaned glass chips, fixing with 2% glutaraldehyde, and
rinsing with water before quick-freezing, freeze-drying, platinum-replica-
tion, and electron microscopy (48–50).
Small Angle X-ray Scattering. SAXS data were collected for ADAMTS13 var-
iants on the SIBYLS beamline 12.3.1.2 at the Advanced Light Source (ALS), a
national user facility operated by the Lawrence Berkeley National Laboratory
and supported by the Director, Office of Science, Office of Basic Energy Sci-
ences, of the US Department of Energy under Contract DE-AC02-05CH11231
(51). All proteins were monodisperse and yielded similar scattering profiles
at three or four concentrations between 0.5 mg/mL and 3.0 mg/mL. Pair
distance distribution functions were obtained using DATGNOM (52).
The quality of the SAXS data was evaluated by comparison with an atomic
model of MDTCS. The M domain was modeled (13) on ADAMTS4 (46), DTCS13
domains were from the corresponding crystal structure (15), and N-linked oli-
gosaccharides were added with GLYPROT (53). This structure was compared
with the experimental scattering profiles using CRYSOL (28), and agreement
was excellent with χ = 1.86 (28). Models (envelopes) were generated from
scattering profiles using DAMMIN (54), averaged (n = 15) using DAMAVER (55),
and superimposed on the atomic structure of MDTCS using SUPCOMB (56).
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